Aytu BioPharma, Inc.
AYTU Healthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.
Follow AYTU
Aytu BioPharma, Inc. (AYTU) Altman Z-score
Aytu BioPharma, Inc.'s Altman Z-score for fiscal 2026 is −4.04, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −4.04 | (0.84) |
| FY2025 | −3.20 | (0.02) |
| FY2024 | −3.18 | (0.49) |
| FY2023 | −2.69 | 2.07 |
| FY2022 | −4.76 | (3.71) |
| FY2021 | −1.05 | (0.71) |
| FY2020 | −0.34 | 4.67 |
| FY2019 | −5.01 | 2.55 |
| FY2018 | −7.57 | (2.78) |
| FY2017 | −4.78 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.07 | — | 0.08 | |
| Retained earnings / total assets | (3.31) | — | −4.64 | |
| EBIT / total assets | (0.08) | — | −0.26 | |
| Market value of equity / total liabilities | 0.38 | — | 0.23 | |
| Sales / total assets | 0.55 | — | 0.55 | |
| Altman Z-score | Distress zone | −4.04 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −10.35 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| UPC Universe Pharmaceuticals INC compare | 0.6× |
| CPHI China Pharma Holdings, Inc. compare | −2.2× |
| AYTU Aytu BioPharma, Inc. | −4.0× |
| BFRI Biofrontera Inc. compare | −5.7× |
| RMTI Rockwell Medical, Inc. compare | −7.4× |
| IXHL Incannex Healthcare Inc. compare | −13.2× |
| TXMD TherapeuticsMD, Inc. compare | −34.4× |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | — |
| BGXXQ Bright Green Corporation compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets